Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia.

The article describes the clinical outcome of 11 patients, particularly nine patients with chronic myeloid leukemia (CML) and two patients with Philadelphia-positive acute lymphoblastic leukemia (Phi+ ALL), who received second-generation tyrosine kinase inhibitor (TKI) treatment in the post-transplant period. The preliminary findings show that application of second generation tyrosine kinase inhibitors is feasible in the post-transplant period. The researchers note that tolerance might be comparable with the application in a standard treatment scenario.